- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- MNKD-201(Nintedanib DPI), Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Fresno, California • Palm Springs, California • Doral, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 584
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- TX000045
- Drug
- Lead sponsor
- Tectonic Operating Company, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pulmonary Fibrosis
- Interventions
- [68Ga]CBP8, Gadoterate Meglumine
- Drug
- Lead sponsor
- Peter Caravan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Scleroderma, Systemic
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Cancer
- Interventions
- Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Interventions
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- Pentoxifylline
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Interstitial Lung Disease
- Interventions
- efzofitimod 450 mg, efzofitimod 270 mg, Placebo
- Drug
- Lead sponsor
- aTyr Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • Miami, Florida + 10 more
- Conditions
- Mediastinal Lymphadenopathy, Sarcoidosis, Pulmonary, Mediastinal Diseases
- Interventions
- Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
- Procedure
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Atorvastatin, Placebo Oral Tablet
- Drug · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis, Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia, Dyspnea, Oxygen Inhalation Therapy
- Interventions
- Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 30 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Neoplasms
- Interventions
- palbociclib plus fulvestrant, fulvestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,772 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 22 more
- Conditions
- Idiopathic Interstitial Pneumonias
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Durham, North Carolina
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Interferon-gamma 1b
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 20 Years to 79 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hermansky-Pudlak Syndrome (HPS)
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 115 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Trametinib
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
- Interventions
- Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
- Other
- Lead sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California